Page 93 - 《中国药房》2022年12期

[12] SUN L，SUN S，WANG T L，et al. Parallel ADR detection 315（6）：F1519-F1525.
based on spark and BCPNN[J]. Tsinghua Sci Technol， [27] GÓRRIZ J L，SOLER M J，NAVARRO-GONZÁLEZ J F，
2018，24（2）：195-206. et al. GLP-1 receptor agonists and diabetic kidney disease：
[13] PARK G，JUNG H，HEO S J，et al. Comparison of data a call of attention to nephrologists[J]. J Clin Med，2020，9
mining methods for the signal detection of adverse drug （4）：947.
events with a hierarchical structure in postmarketing [28] ÜNÜBOL M，GENCER F，AKDAM H，et al. Exena-
surveillance[J]. Life（Basel），2020，10（8）：138. tide-induced acute renal failure：a case report[J]. Tjem，
[14] BATE A，LINDQUIST M，EDWARDS I R，et al. A data 2013，17（3）：68-70.
mining approach for signal detection and analysis[J]. [29] TAYLOR S R，MOODY M T. Acute kidney injury occur-
Drug Saf，2002，25（6）：393-397. ring in a patient initiated on dulaglutide[J]. J Pharm Technol，
[15] 伏箫燕，陈力，陈成，等.基于 FAERS 数据库利拉鲁肽不 2018，34（5）：231-232.
良反应信号挖掘与分析[J].中国医院药学杂志，2020，40 [30] SHYANGDAN D S，ROYLE P L，CLAR C，et al. Glu-
（18）：1957-1961. cagon-like peptide analogues for type 2 diabetes mellitus：
[16] GILBERT M P，PRATLEY R E. GLP-1 analogs and DPP-4 systematic review and meta-analysis[J]. BMC Endocr
inhibitors in type 2 diabetes therapy：review of head-to- Disord，2010，10：20.
head clinical trials[J]. Front Endocrinol（Lausanne），2020， [31] HTIKE Z Z，ZACCARDI F，PAPAMARGARITIS D，et al.
11：178. Efficacy and safety of glucagon-like peptide-1 receptor
[17] HONIGBERG M C，CHANG L S，MCGUIRE D K，et al. agonists in type 2 diabetes：a systematic review and
Use of glucagon-like peptide-1 receptor agonists in patients mixed-treatment comparison analysis[J]. Diabetes Obes
with type 2 diabetes and cardiovascular disease：a review Metab，2017，19（4）：524-536.
[J]. JAMA Cardiol，2020，5（10）：1182-1190. [32] GOSHO M. Risk of hypoglycemia after concomitant use
[18] HOROWITZ M，ARODA V R，HAN J，et al. Upper and/ of antidiabetic，antihypertensive，and antihyperlipidemic
or lower gastrointestinal adverse events with glucagon- medications：a database study[J]. J Clin Pharmacol，2018，
like peptide-1 receptor agonists：incidence and consequences 58（10）：1324-1331.
[J]. Diabetes Obes Metab，2017，19（5）：672-681. [33] FILIPPATOS T D，PANAGIOTOPOULOU T V，ELISAF
[19] EGAN A G，BLIND E，DUNDER K，et al. Pancreatic safety M S. Adverse effects of GLP-1 receptor agonists[J]. Rev
of incretin-based drugs：FDA and EMA assessment[J]. N Diabet Stud，2014，11（3/4）：202-230.
Engl J Med，2014，370（9）：794-797. [34] EMA. Assessment report：semaglutide[EB/OL]. [2022-04-
[20] FDA. NDA 22-341 VICTOZA（liraglutide [rDNA origin] 12]. http：//www.ema.europa.eu/en/documents/product-
injection）[EB/OL]. [2021-11-11]. https：//www.fda.gov/ information/wegovy-epar-product-information_en.pdf.
media/78468/download. [35] ANDERSON S L，TRUJILLO J M. Lixisenatide in type 2
[21] VETTER M L，JOHNSSON K，HARDY E，et al. Pan- diabetes：latest evidence and clinical usefulness[J]. Ther
creatitis incidence in the exenatide BID，exenatide QW， Adv Chronic Dis，2016，7（1）：4-17.
and exenatide QW suspension development programs： [36] TRUJILLO J M，NUFFER W，ELLIS S L. GLP-1 recep-
pooled analysis of 35 clinical trials[J]. Diabetes Ther， tor agonists：a review of head-to-head clinical studies[J].
2019，10（4）：1249-1270. Ther Adv Endocrinol Metab，2015，6（1）：19-28.
[22] STRECKEL E，BRAUN-REICHHART C，HERBACH N， [37] YU M Z，BENJAMIN M M，SRINIVASAN S，et al. Battle
et al. Effects of the glucagon-like peptide-1 receptor agonist of GLP-1 delivery technologies[J]. Adv Drug Deliv Rev，
liraglutide in juvenile transgenic pigs modeling a pre- 2018，130：113-130.
diabetic condition[J]. J Transl Med，2015，13：73. [38] MACCONELL L，GURNEY K，MALLOY J，et al. Safety
[23] SMITS M M，VAN RAALTE D H. Safety of semaglu- and tolerability of exenatide once weekly in patients with
tide[J]. Front Endocrinol（Lausanne），2021，12：645563. type 2 diabetes：an integrated analysis of 4 328 patients
[24] TILINCA M C，TIUCA R A，BURLACU A，et al. A 2021 [J]. Diabetes Metab Syndr Obes，2015，8：241-253.
update on the use of liraglutide in the modern treatment of [39] 张伊洁，郭宁子，刘万卉，等.缓控释注射剂中丙交酯乙交
“diabesity”：a narrative review[J]. Medicina（Kaunas）， 酯共聚物（PLGA）分析方法的研究进展[J].中国医药工
2021，57（7）：669. 业杂志，2019，50（10）：1180-1187.
[25] GAO L，YU S Q，CIPRIANI A，et al. Neurological mani- [40] DEYOUNG M B，MACCONELL L，SARIN V，et al.
festation of incretin-based therapies in patients with type 2 Encapsulation of exenatide in poly-（D，L-lactide-co-
diabetes：a systematic review and network meta-analysis glycolide）microspheres produced an investigational long-
[J]. Aging Dis，2019，10（6）：1311-1319. acting once-weekly formulation for type 2 diabetes[J].
[26] DIETER B P，ALICIC R Z，TUTTLE K R. GLP-1 receptor Diabetes Technol Ther，2011，13（11）：1145-1154.
agonists in diabetic kidney disease：from the patient-side （收稿日期：2021-11-16 修回日期：2022-03-21）
to the bench-side[J]. Am J Physiol Renal Physiol，2018， （编辑：陈 宏）

中国药房 2022年第33卷第12期 China Pharmacy 2022 Vol. 33 No. 12 ·1491 ·